Voltage-gated sodium channels (NaChs) are relevant targets for pain, epilepsy, and a variety of neurological and cardiac disorders. Traditionally, it has been difficult to develop structure-activity relationships for NaCh inhibitors due to rapid channel kinetics and state-dependent compound interactions. Membrane potential (V m ) dyes in conjunction with a high-throughput fluorescence imaging plate reader (FLIPR) offer a satisfactory 1st-tier solution. Thus, the authors have developed a FLIPR V m assay of rat Na v 1.2 NaCh. Channels were opened by addition of veratridine, and V m dye responses were measured. The IC 50 values from various structural classes of compounds were compared to the resting state binding constant (K r ) and inactivated state binding constant (K i ) obtained using patch-clamp electrophysiology (EP). The FLIPR values correlated with K i but not K r . FLIPR IC 50 values fell within 0.1-to 1.5-fold of EP K i values, indicating that the assay generally reports use-dependent inhibition rather than resting state block. The Library of Pharmacologically Active Compounds (LOPAC, Sigma) was screened. Confirmed hits arose from diverse classes such as dopamine receptor antagonists, serotonin transport inhibitors, and kinase inhibitors. These data suggest that NaCh inhibition is inherent in a diverse set of biologically active molecules and may warrant counterscreening NaChs to avoid unwanted secondary pharmacology. (Journal of Biomolecular Screening 2006: 29-39) 
INTRODUCTION

V
OLTAGE-GATED SODIUM CHANNELS (NaChs) play key roles in determining neuronal excitability. 1, 2 These channels are critically involved in the generation of the neuronal action potential, as they mediate the initial inward current during depolarization. Similarly, they are responsible for this same process in cardiac tissue and other excitable cells. They represent the molecular site of action of various neurotoxins, local anesthetics, anticonvulsants, and antiarrhythmics. 2, 3 NaChs are composed of an α pore-forming subunit that can associate with auxiliary β subunits. 4 Nine α subunits, named Na v 1.1 through Na v 1.9, and 3 β subunits, named β 1 , β 2 , and β 3 , of NaChs have been cloned and expressed. 4, 5 Several additional atypical sodium channel-like proteins have been cloned but still await functional expression. 4 The α subunits are large (~260 kD) membranespanning proteins composed of 4 segments that each contain 6 transmembrane regions. When expressed in mammalian cells, recombinant α subunits form functional channels with appropriate ion permeation, voltage sensing, and inactivation properties. 4 The β subunits play modulatory roles in channel gating and regulation of expression levels. 5 The various α and β subunits have distinct spatial and temporal patterns of expression throughout the nervous system and nonneuronal tissues.
2 Na v 1.2 (rat brain type IIa) represents a highly tetrodotoxin (TTX)-sensitive NaCh that is broadly expressed in neurons. 4 State-dependent block of NaChs is an important mechanism of action of many anticonvulsants, local anesthetics, and antiarrhythmics, [6] [7] [8] [9] [10] [11] [12] [13] which generally exhibit greater affinity for the open or inactivated states of the channel than for the resting state ( Fig. 1) and, as such, are considered use-dependent blockers. anesthetic diphenhydramine. These compounds exhibit~100-fold higher affinity for the inactivated state (defined by the dissociation constant, K i ) compared to the resting state (defined by the dissociation constant, K r ) of the channel. [9] [10] [11] [12] Many compound therapeutics designed to interact with other molecular targets have also been shown to promiscuously inhibit resting or inactivated NaChs. This secondary pharmacology has been proposed to underlie toxic side effects such as cardiotoxicity. 15 For example, amitriptyline, a common antidepressant, can cause cardiac toxicity with overdose. At these high concentrations, it blocks human cardiac NaChs in a state-dependent manner. It exhibits high affinity for the inactivated state of the channel and low affinity for the resting state. Recovery from inactivated state block is relatively slow and may mechanistically contribute to the observed cardiotoxic side effects. 15 Taking advantage of the electrogenicity of NaChs, we have developed a homogeneous, fluorescence-based, functional highthroughput assay of NaCh activity using the Molecular Devices FLIPR Membrane Potential (V m ) assay kit in stable rNa v 1.2-HEK cells. Changes in fluorescence using the fluorescence imaging plate reader (FLIPR) V m indicator dye linearly correlate with direct electrophysiology (EP) measurements of membrane potential in current clamped cells. 16 Thus, rNa v 1.2-HEK cells are loaded with the fluorescent V m indicator dye, and a change in cellular membrane potential in response to the NaCh inactivation inhibitor, veratridine, 17 is read on a FLIPR. A similar FLIPR V m dye assay format has been used previously for pharmacological profiling of rNa v 1.2, hNa v 1.5, rNa v 1.8, and native TTX-sensitive NaChs in rat cerebellar granule neurons. 18 However, a comprehensive analysis of how the FLIPR data relate to resting or inactivated state block, as well as the assay's utility to profile small molecules with a large dynamic range of potencies, particularly those with high potencies (IC 50 values ≤ 400 nM), was not presented. Thus, to address some of these outstanding mechanistic and dynamic range issues and to extend the utility of this assay to selectivity screening for unknown NaCh blockers, we describe in this study the development of a rNa v 1.2-HEK cell-based assay, show detailed comparison of the FLIPR-based pharmacological profiles compared to EP K i and K r values for a large collection of compounds with several different chemotypes over a wide range of potencies, and present the results from a screen of the Library of Pharmacologically Active Compounds (LOPAC, Sigma). Our data suggest that this FLIPR assay correlates better with K i values than with K r values across a wide range of compound potencies and varying chemotypes. These data also show that the assay can be used as a counterscreen to identify compounds that exhibit secondary pharmacology at NaChs to avoid potential side effects.
MATERIALS AND METHODS
Materials
Cell culture and molecular biology reagents were purchased from Invitrogen Corporation (Carlsbad, CA) unless otherwise noted. Proprietary compounds from the Purdue Pharma internal library were synthesized to > 97% purity using standard protocols or as referenced. All other chemicals and reagents were purchased from Sigma (St. Louis, MO).
Cloning and stable rNa v 1.2-HEK cell line development
The plasmid pCMV-RIIA, which encodes rNa v 1.2 under control of the cytomegalovirus (CMV) promoter, was obtained from Dr. Alan Goldin, University of California, Irvine. The construct also contained the neomycin gene for selection of stable cell lines with the neomycin analog G418. HEK-293 cells were plated at a density of 3 × 10 5 cells per well in a 6-well plate and transfected the following day with pCMV-RIIA DNA using Transfast reagent (Promega Inc., Madison, WI). After 3 weeks of selection in 400 µg mL -1 G418, resistant colonies were isolated, expanded, and plated in 35-mm dishes coated with poly-D-lysine for EP analysis. Several clones expressing TTX-sensitive inward currents were identified. The clone that expressed the largest amplitude currents was expanded and further EP analyses performed as described below. -1 lower than that for the external solution. The pipette resistances ranged from 1.5 to 3 MΩ. Residual series access resistance was in the range of 0.5 to 1.2 MΩ after partial (75%-80%) cancellation using built-in amplifier circuitry. Drug stock solutions and intervening intervals of wash were applied through a linear array of flow pipes (Drummond Microcaps, 2-mL, 64-mm length), producing full solution exchange within a few hundred msec. Drug stock solutions of 10 to 30 mM were prepared in DMSO and then were diluted into working external saline solutions on each day of experimentation. For all drugs, the concentration of DMSO in most experiments did not exceed 0.1% by volume, which had no measurable effect on NaCh current (I Na ).
Electrophysiology protocols
Sodium currents in rNa v 1.2-HEK cells are half-maximally activated by depolarization to -18.2 ± 0.3 mV (n = 13) with a steepness of 5.7 ± 0.3 mV and reach maximum at~0 mV. 21 With 100-msec depolarizing conditioning prepulses, half-maximal inactivation occurs at -53.9 ± 1.7 mV with the slope of 6.4 ± 0.1 mV per e-fold change in membrane potential (n = 17). 21 The channels recover from inactivation following a double-exponential time course: 80% to 85% of channels recovered within the first 2-5 msec; the remaining 15% to 20% of channels recovered more slowly, with a time constant of ≥ 200 msec. Most compounds tested by these methods significantly retard the recovery of rNa v 1.2 channels from inactivation. 21, 22 Based on this knowledge, we designed simplified protocols to assess inhibition of resting and inactivated states of the channels for this study. To quantify the affinity toward resting state, cells were held at -110 mV and pulsed to 0 mV every 10 sec to cause maximal Na + current. At such a negative voltage, there was virtually no resting inactivation (< 1%). Steady-state currents were measured after ≥ 2 min in control or drug-containing solutions. The magnitude of inhibition was measured at high drug concentration, usually 3 µM. From the fractional response (FR) at this antagonist concentration, [antagonist], the estimate for the apparent dissociation constant for resting state, K r , was obtained using the following equation: K r = {FR/(1 -FR)}*[antagonist] (assuming 1:1 binding stoichiometry). To measure the affinity toward the inactivated state, a double pulse protocol was used. From a holding voltage of -110 mV, cells were depolarized by a conditioning step to -20 mV for 3 sec. This step caused complete inactivation of NaChs and was long enough to ensure steady-state binding to inactivated channels, even for the slowest compounds. This step was followed by a short (5-msec) hyperpolarizing gap back to -110 mV, which was sufficient to permit > 80% recovery from fast inactivation in control. Then, a 5-msec test pulse to 0 mV was applied to measure the proportion of channels available for activation. In the presence of a drug, only unbound channels have a chance to recover from inactivation at a normal pace because repriming from inactivation is significantly retarded by the drug binding. Thus, the current caused by the test pulse reported the proportion of liganded (and blocked) channels. For some compounds presented in this study, a single concentration was empirically chosen that caused 50% inhibition. 23 From the FR at this concentration, the estimate for K i was obtained using the following equation: 
Data analysis
The concentration of veratridine yielding 50% of its maximal effect (EC 50 value) or the concentration of antagonist yielding 50% of its maximal inhibition (IC 50 value) was calculated from theoretical curves generated using nonlinear regression curve fitting analysis in GraphPad Prism, version 3.02 (San Diego, CA). Linear regression analysis and corresponding statistical significance were carried out using GraphPad Prism 3.02.
RESULTS
Membrane potential (V m ) dye fluorescence responses to varying concentrations of veratridine were measured in rNa v 1.2-HEK cells in the 96-well format on a FLIPR plate reader (Fig. 2) . Veratridine-induced increases in fluorescence were reproducible and concentration dependent. The average signal-to-background (S/B) ratio, as determined by fluorescence change (∆F) after 25 µM veratridine divided by ∆F after buffer only, was 20.4 ± 1.2 (n = 16 plates). The average EC 50 value for veratridine was 22.2 ± 3.2 µM (n = 3), consistent with previously reported values.
A variety of NaCh reference antagonists, as previously characterized by EP 6, 23 or the Na + influx assay, 24 were tested for their ability to inhibit the response to 25 µM veratridine. Inhibition was dependent on compound concentration, except for lidocaine, which exhibited no inhibitory activity up to 66 µM (Fig. 3) . Rank order of potency for compounds that exhibited inhibition was as follows: TTX >> flunarizine > pimozide >> lamotrigine > carbamazepine. Respectively, average IC 50 values were 0.0042 ± 0.0006 µM (n = 16), 0.154 ± 0.024 µM (n = 16), 0.744 ± 0.155 µM (n = 8), 19.5 ± 4 µM (n = 8), and 144 ± 30.7 µM (n = 8), consistent with the literature. 6, 23, 24 Lack of lidocaine inhibition at the concentrations tested also is consistent with a previously reported veratridine-based V m assay 18 but is inconsistent with both literature 6 and in-house EP K i values (~10 µM; data not shown).
To validate the FLIPR V m dye assay with respect to traditional values derived by EP, antagonists active in the FLIPR assay were characterized by EP for state-dependent block of whole-cell currents in rNa v 1.2-HEK cells. In a representative experiment, very little block was observed with 3 µM of compounds G or E (Purdue Pharma L.P. proprietary compounds) at a negative holding potential of -110 mV ( Fig. 4A; Table 1 ), suggesting low affinity of these compounds to the resting state of rNa v 1.2 channels. However, in a double pulse protocol where a depolarizing prepulse to -20 mV is used to drive all the channels into the inactivated state, the percent inhibition increased dramatically (Fig. 4B) , suggesting higher affinity inhibition of inactivated channels as compared to resting block. Specific control and compound current traces, indicated by arrows in panels A and B, also reveal a greater degree of compound blocking activity in the inactivated state than in the resting state (Fig. 4C-D) . Under inactivated state conditions, current amplitudes overall are appropriately lower. This is due to a slow inactivation process that occurs during the depolarizing prepulse that results in a lower number of channels available for opening. Compounds such as these, with profiles of greater block under inactivated state conditions than in the resting state, are considered state-dependent inhibitors.
Validation with respect to EP was conducted for a set of 21 compounds representing several different structural classes, including known NaCh blockers, 22, 23 as well as compounds whose NaCh activity was previously uncharacterized. 25 Figure 6 . Mock plates received 0.8% DMSO in assay buffer (no compounds), followed by addition of 25 µM veratridine. Responses to veratridine were consistent throughout all positive control wells in 96-and 384-well formats. Inclusion of TTX (2 µM) blocked the responses completely in the negative control wells. Average Z′ factors for 96-and 384-well plates were 0.51 ± 0.02 (n = 35) and 0.36 ± 0.05 (n = 6), respectively.
Using the FLIPR V m dye 96-well formatted screening assay, we screened LOPAC to determine the proportion of known, biologically active molecules in this library that exhibit nonspecific activity at rNa v 1.2. The screening concentration was 1 µM. The average Z′ factor was 0.49 ± 0.04 (n = 16), and the average S/B was 23.6 ± 1.2 (n = 16). Hit cutoff was set to 50% inhibition of the response to 25 µM veratridine. Of the 16 LOPAC plates, 99 active wells were identified and cherry-picked for single-point confirmation at 1 µM. Of these, 10 wells confirmed (0.8% confirmed hit rate). The purified, crystalline form of these 10 LOPAC hits was ordered from Sigma and retested in concentration-inhibition format. Nine of the 10 reconfirmed.
The identities and IC 50 profiles for the confirmed hits from the LOPAC are shown in Table 2 . One compound, flunarizine, is a reported NaCh inhibitor with submicromolar potency. 18, 27, 28 The additional 8 compounds have other reported pharmacological activities, including dopamine receptor inhibition, serotonin receptor agonism or uptake inhibition, and diacylglycerol kinase inhibition. For these compounds, moderate-to high-potency NaCh inhibition is a previously uncharacterized activity. Nonetheless, NaCh inhibition obtained using the FLIPR V m dye assay for these compounds was confirmed in the EP K i assay ( Table 2) . These data were analyzed by linear regression to assess the correlation between the FLIPR V m assay IC 50 values and EP K i values in this newly discovered sodium channel inhibitor data set. The correlation between the 2 assays for these LOPAC hits was significant, with r 2 = 0.76, p < 0.01. This level of correlation matches very closely the value achieved with the 21 known sodium channel blocker compound correlation described earlier. 
DISCUSSION
Sodium channels are critically involved in the generation of action potentials in neurons, cardiac tissue, and other excitable cells. 2 Deregulation of neuronal NaCh function can underlie diseases of nervous system hyperexcitability such as chronic neuropathic pain, head trauma, epilepsy, and stroke. 2 Similarly, deregulation of these channels in the heart can lead to long QT syndrome, 29, 30 which increases the risk of fatal ventricular arrhythmias. Deregulation in skeletal muscle can lead to periodic paralysis. 31, 32 Compound therapeutics designed to pharmacologically target other mechanisms have been shown to promiscuously inhibit cardiac and neuronal NaChs. [33] [34] [35] [36] In neurons, this secondary pharmacology may underlie some additional therapeutic effects, such as the antihyperalgesic efficacy of some antidepressants. 36 In the heart, it may underlie toxic side effects, such as cardiotoxicity, that is observed with some antidepressants and psychotropic agents. [33] [34] [35] Thus, NaChs represent key targets for alleviating debilitating disease, as well as key mechanisms for deleterious side effects of some compound therapeutics.
Conventional methods for assaying NaCh activity include radiolabeled toxin-binding assays, 37 ]saxitoxin, or other NaCh-selective radiolabeled toxin binding to NaChs. The advantage of these assays is amenability to high throughput, especially if designed in the scintillation proximity assay (SPA) format. A drawback, however, is that these assays do not have a functional endpoint; thus, detection is restricted to compounds that interact directly, or allosterically, with the specific toxin-binding site being measured. In addition, these assays generate significant quantities of costly radioactive waste.
Radioactive ion influx assays involve measuring compound inhibition of [ 39,40 Sufficient S/B is achieved in the presence of a NaCh inactivation inhibitor, such as veratridine. 17 The advantage of these assays is that they measure functional NaCh activity and thus are less limited by the compound mechanism of interaction. Assay throughput is significantly higher than traditional EP approaches. Nonetheless, multiple wash steps are required, necessitating a nonhomogeneous assay format. In addition, they produce large quantities of radioactive waste. The incubation time is relatively long, 
Gcommonly 1 h, introducing the potential to measure interaction with processes downstream of the channel. And finally, they require the use of a chemical modifier of channel inactivation, introducing the risk of 1) missing compounds that interact with channel conformations that occur in the absence of the inactivation inhibitor and/or 2) detecting compounds that interfere directly with the chemical modifier and that would not otherwise affect NaCh activity under more natural activation conditions.
Electrophysiological patch-clamp assays 20, 41 measure the amount of current necessary to clamp the cell membrane at a given V m after depolarization-induced channel activation. To characterize the compound mechanism of interaction or state dependence, many variations on the basic assay protocol are commonly used.
These include varying the frequency, length, and magnitude of the depolarizing stimulus; the presence or absence of prepulse depolarization; and the length and magnitude of prepulse depolarization. In this regard, EP offers the advantages of a functional, nonradioactive readout with exquisite time resolution and mechanistic detail. However, traditional EP has inherent limitations, including low throughput (1 cell assayed at a time), a requirement for highly skilled technical personnel with specific expertise, and specialized equipment incompatible with standard laboratory robotics. Although recent advances in higher throughput EP such as IonWorks or PatchXpress (both Molecular Devices Inc.) can theoretically reduce the magnitude of these limitations, these technologies are still relatively expensive, not yet integrated as standard screening laboratory equipment, and not yet empirically proven to deliver the same quality of information regarding compound affinity and mechanism of action as manual patch-clamp techniques can deliver.
Cellular toxicity assays involve measuring cell death after induction of intracellular Na + ion accumulation in the presence of a NaCh inactivation inhibitor, such as veratridine, and a Na + /K + ATPase inhibitor to prevent Na + ion homeostasis. 42 The advantage of these assays is that they are functional and high throughput. The disadvantages include a long reaction incubation time of about 24 h, the use of a chemical modifier of channel inactivation, and the use of a Na + ion extrusion pump inhibitor. Such complexity in chemical modifications to the cellular system may introduce artifacts that are modified by the test compounds but that are not relevant to native channel physiology. Thus, we have described and characterized in detail a fluorescence-based FLIPR V m assay approach to measure NaCh activity. The assay can be performed in either 96-or 384-well formats; is homogeneous, fluorescence based, and kinetic; and uses relatively short reaction times of approximately 5 min. Screening Z′ factors were moderate to good in both microtiter formats, although the 96-well format was clearly better. Variability in positive and negative controls in the 384-well format led to a marginally satisfactory average Z′ factor. Most likely, this could be improved with more assay optimization, such as better mixing upon agonist addition in the FLIPR; more extensive cell density optimization; and/or reisolation of a more robust rNa v 1.2-HEK cell line with greater S/B. The assay reported appropriate pharmacological profiles as compared to EP-determined K i values. Although a similar FLIPR V m assay of NaChs has been reported previously, 18 our data have substantially extended the meaning and characterization of the data generated by this type of assay. We have shown that over a chemically diverse set of small molecule compounds with potent K i values, in addition to TTX, the FLIPR V m data closely match that of EP. Moreover, the data significantly correlated with EP K i , but not EP K r , across a large dynamic range of compound potencies (ranging from single nanomolar to hundreds of micromolar K i values), suggesting that the assay most accurately approximates open or inactivated state block of the channel but not resting state block.
Several issues with the FLIPR V m assay remain outstanding and confer some limitations. Similar to the radiolabeled ion influx assays and the cellular toxicity assays, the FLIPR V m assay relies on the use of veratridine, a chemical modifier of channel inactivation, and in this respect suffers the same drawbacks already discussed. Furthermore, veratridine modifies channel inactivation by slowing it down significantly and stabilizing the channel in the open state. Thus, theoretically, this assay by definition does not measure resting state block or K r , as we have observed through lack of correlation between FLIPR IC 50 and EP K r values. But more important, this assay also might not be measuring inactivated state block. Interestingly, however, the data do statistically correlate with inactivated state block (K i ). Therefore, it is possible that the assay measures open state block of the channel. This idea is supported by our observed lack of lidocaine inhibition at concentrations up to 66 µM, which has also been previously reported in a similar assay 18 (IC 50 value: 190 µM). In contrast, the EP K i for lidocaine is~10 µM, and the EP K r is > 100 µM. 6 Mechanistically, lidocaine has little to no affinity for the resting or open state of the NaCh. Its usedependent inhibition is purely derived from binding to the inactivated, but not open, state. 6 Comparison of our FLIPR V m assay data to EP K i values suggests that such a compound is relatively rare and that most use-dependent compounds bind with similar affinity to open and inactivated states but with substantially lower affinity to the resting state. A substantial number of compounds with this type of mechanistic profile have been confirmed using EP. Such compounds include bupivacaine, imipramine, carbamazepine, and diphenhydramine. 13, 43 Thus, based on this collective evidence, an assay that measures open state block theoretically should approximate EP K i values relatively well. Nonetheless, under natural conditions, the open state of the NaCh is extremely transient (1-2 msec); most compounds are thought not to bind this rapidly. Therefore, this assay risks reporting information that is not highly relevant to a natural physiological state.
Alternatively, correlation between the FLIPR V m assay with EP K i values may be mechanistically related to the conformational state of the channel. 9 If chemical activation of NaChs by veratridine results in a conformational state similar but not identical to a state induced by a depolarization protocol that drives the channel into the inactivated state, then compounds may exhibit similar affinities, as the receptor target is generally the same. Such a model could also account for an occasional outlier, such as lidocaine, which lacks inhibition in the FLIPR assay, because such compounds may only bind if the exact conformational state they require is strictly achieved. To fully delineate the exact theoretical model that underlies the FLIPR V m assay, further investigation into the mechanistic basis for this assay is warranted.
In screening the LOPAC library, we have shown that a significant number of biologically active compounds that were designed to interact with other targets exhibit high-to moderate-potency NaCh inhibition. A similar result was seen for the set of proprietary Purdue compounds presented in Table 1 , which were designed in the context of discovery programs unrelated to NaChs. These data demonstrate the relevance and importance of including a relatively easy and high-throughput functional assay of NaChs as a counterscreen assay for discovery programs aimed at identifying compounds active at other targets.
The FLIPR V m assay, with its various caveats taken into account, does provide a convenient, high-throughput, and useful
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Journal of Biomolecular Screening 11(1); 2006 www.sbsonline.org 37 method to screen for NaCh inhibitor compounds, with statistically significant correlation to use-dependent block. The assay can be used to prioritize compounds for potency at NaChs or for selectivity counterscreening against these channels. Subsequently, laterstage compounds of highest interest would still benefit from detailed mechanistic analysis by EP.
